LEE'S PHARM(00950): Innovent obtains approval from the National Medical Products Administration.
Li's Grand Pharmacy (00950) announced that on March 17, 2026, the China National Medical Products Administration (National Medical Products Administration) has approved Incelace (owned by Cosette Pharmaceuticals and licensed to Li's Grand Pharmacy) for the treatment of postmenopausal women with moderate to severe symptoms (excluding urinary symptoms) of vulvar-vaginal atrophy.
LEE'S PHARM(00950) announced that on March 17, 2026, the China National Medical Products Administration (NMPA) has approved the use of Yinerzha (owned by Cosette Pharmaceuticals and licensed to LEE'S PHARM) for the treatment of postmenopausal women with moderate to severe symptoms (excluding symptoms of the genitourinary system) of vulvar and vaginal atrophy.
Following the successful completion of Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trials conducted by our wholly-owned subsidiary Zhaokun Pharmaceutical (Hefei) Co., Ltd., this approval marks an important milestone.
Related Articles
AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.
CHINA ECOTOUR (01371) is seeking for a restructuring and formulating proposed restructuring terms.
SIMCERE PHARMA (02096): Ma Bao Wen appointed as Co-Secretary of the Company
AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.
CHINA ECOTOUR (01371) is seeking for a restructuring and formulating proposed restructuring terms.
SIMCERE PHARMA (02096): Ma Bao Wen appointed as Co-Secretary of the Company
